An Open-Label Biomarker Study of BHV-1400 in IgA Nephropathy

Biohaven Therapeutics Ltd.

Summary

The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).

Eligibility

Age range: 18–65 years
Sex: All
Healthy volunteers: No

Detailed criteria

Key Inclusion Criteria: 1\. Participants must have biopsy-confirmed IgA Nephropathy Key Exclusion Criteria: 1. Any secondary IgAN 2. Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause

Interventions

Drug
BHV-1400
BHV-1400 is delivered subcutaneously (SC)

Locations (12)

Site-001
Farmington, Connecticut
Site-003
Miami Lakes, Florida
Site-011
Miami Lakes, Florida
Site-013
Orlando, Florida
Site-005
Pembroke Pines, Florida
Site-008
Lawrenceville, Georgia